Claims extracted
18
sentences that state something as happening or true
Uncertain
11%
2 of 18 hedged
("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
66/100
New York Post's corrections and
hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
10
Health
Same framing elsewhere
1
articles that frame the event the way this one does
The agency is ordering drugmakers to update safety labels on their popular weight-loss and diabetes treatments, alerting patients and health care providers to the potential danger.
asserted
agency → order → danger
Warning signs may include painless vision loss in one eye — which patients may first notice upon waking — as well as blurred vision, missing patches of sight, distorted colors and hazy spots affecting central vision.
uncertain
patients → include → vision
“Patients should contact their health care professional right away if they have any of these symptoms,” the FDA wrote in a drug safety communication issued Nov. 9.
asserted
FDA → contact → communication
There is currently no proven treatment to cure or reverse vision loss caused by NAION, which can lead to blindness.
asserted
which → be → blindness
The warning follows a 2024 study that found diabetes patients taking semaglutide — the active ingredient in GLP-1 drugs Ozempic and Wegovy — were four times more likely to develop NAION than those who weren’t prescribed the medication
“Although FDA identified several limitations of this study, the agency determined that further assessment of the potential increased risk for NAION was warranted,” the agency wrote.
asserted
agency → follow → NAION
The FDA said it conducted a “comprehensive evaluation” of available clinical trial data, animal data and post-marketing information, including observational studies and case reports.
asserted
it → say → studies
The agency found that NAION cases had been reported across all currently marketed GLP-1 products.
asserted
cases → find → products
However, it said those reports were difficult to interpret because NAION risk factors often overlap with conditions common among patients taking the medications.
asserted
factors → say → medications
The FDA also said it was unable to identify a mechanism explaining how GLP-1 drugs might increase the risk of the eye condition.
uncertain
drugs → say → condition
Still, based on the available evidence, the agency “concluded that there is a potential increased risk of rare NAION events” among GLP-1 users.
asserted
agency → base → users
The treatments work by mimicking hormones produced in the gut in response to eating, helping regulate appetite, digestion and blood sugar.
asserted
treatments → work → appetite
The class includes blockbuster treatments such as Ozempic, Wegovy, Zepbound and Mounjaro, which are widely prescribed to treat Type 2 diabetes and help patients lose excess weight.
asserted
patients → include → weight
Some GLP-1 drugs have also been approved for additional uses, including reducing the risk of major cardiovascular events and worsening kidney disease.
asserted
drugs → approve → disease
Others have been cleared to treat obstructive sleep apnea and liver disease.
asserted
Others → clear → apnea
The drug class also carries a boxed warning about the potential risk of thyroid tumors.
asserted
class → carry → tumors
Now, the FDA is urging health care providers to tell patients taking GLP-1s to immediately report any new, painless vision loss, visual field deficits or other visual disturbances in one eye.
asserted
FDA → urge → eye
“If NAION is suspected, promptly refer the patient to an ophthalmologist for evaluation,” the agency wrote.
asserted
agency → suspect → evaluation
“Consider discontinuing the GLP-1 RA in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk.”
asserted
benefits → consider → risk
The Aporia
